Repligen Earnings: What To Look For From RGEN

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours. Here’s what investors should know.

Repligen beat analysts’ revenue expectations by 4.1% last quarter, reporting revenues of $182.4 million, up 14.8% year on year. It was a strong quarter for the company, with a solid beat of analysts’ revenue estimates and full-year revenue guidance beating analysts’ expectations.

Is Repligen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Repligen’s revenue to grow 17.4% year on year to $181.9 million, improving from the 9.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.42 per share.Repligen Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Repligen has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Repligen’s peers in the life sciences tools & services segment, some have already reported their Q3 results, giving us a hint as to what we can expect. West Pharmaceutical Services delivered year-on-year revenue growth of 7.7%, beating analysts’ expectations by 2.1%, and Medpace reported revenues up 23.7%, topping estimates by 2.7%. West Pharmaceutical Services traded up 7.5% following the results while Medpace was also up 8.9%.

Read our full analysis of West Pharmaceutical Services’s results here and Medpace’s results here.

There has been positive sentiment among investors in the life sciences tools & services segment, with share prices up 7.6% on average over the last month. Repligen is up 36.9% during the same time and is heading into earnings with an average analyst price target of $180.33 (compared to the current share price of $169.86).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Ver comentarios